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ABSTRACT
Despite the well-known health benefits associated with physical activity
(PA), the majority of people with Parkinson’s disease (pwPD) and people with
stroke do not meet national PA guidelines. As a result, these two groups of
people are at increased risk for development of cardiovascular disease,
additional disability and death.
Walking as a mode of PA has been shown to improve the health of both
pwPD and people with stroke. In fact, a step count of >6000 steps per day is
related to a decreased risk of subsequent cardiovascular events in people with
stroke. Daily walking is also strongly recommended by the U.S. surgeon general
and national PA guidelines. Currently, however, guidelines do not recommend a
specific daily step count for pwPD or stroke and the relationship between daily
steps and health in these individuals is unclear.
The overall purpose of the following two studies was to identify daily step
counts associated with health outcomes in pwPD and people with stroke.
Specifically for pwPD (Chapter 2), the purpose was to 1) determine a step
threshold that corresponds to meeting aerobic PA guidelines, 2) determine
effects of treadmill exercise performed at varying intensities on PA and 3)
quantify the relationship between changes in daily steps and fitness. For people
with stroke (Chapter 3) the purpose was to 1) determine which factors at two
months post-stroke can predict daily step counts at one year, and 2) determine
v

what step count at two months corresponds to obtaining >6000 daily steps at one
year post-stroke.
Data for both studies were obtained from publicly available datasets. The
first study included 110 individuals with de novo Parkinson’s disease who were
allocated to one of three groups (high-intensity treadmill exercise, moderateintensity treadmill exercise or control) for six months. Baseline step data and
Receiver Operating Characteristic (ROC) curves were used to determine which
step count corresponded to meeting PA guidelines. The effect of treadmill
exercise on PA was examined in those below the step threshold (i.e. the least
active participants). Pearson’s r correlations determined the relationship between
daily steps and fitness. The second study included 206 participants with stroke
who were allocated to one of three groups (36 sessions of body weight–
supported treadmill training at two months post-stroke, 36 sessions of body
weight–supported treadmill training at six months post-stroke, or 36 sessions of
progressive supervised home exercise program). Daily steps were assessed at
two months and one year post-stroke. Linear regression was used to predict daily
step counts at one year based on factors including age, gender, race and/or
ethnicity, stroke severity, walking speed and endurance, fitness, motor function,
balance and balance confidence. A Receiver Operating Characteristic (ROC)
curve determined which step count corresponded to reaching >6000 steps at one
year.
Results indicate that for pwPD, a daily step count of >4200 corresponds to
meeting PA guidelines. For participants with <4200 daily steps at baseline, high-
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intensity treadmill exercise led to improvements in daily steps but these changes
were not associated with changes in fitness. Overall, pwPD should be
encouraged to take >4200 daily steps in order to meet PA guidelines through
walking. For people with stroke, daily steps and balance at two months poststroke were the strongest predictors of future daily steps. Thus, improving daily
PA and balance early after stroke may be necessary to increase PA levels at one
year post-stroke. A step count of >1632 steps per day at two months post-stroke
corresponded to obtaining >6000 daily steps at one year.
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CHAPTER 1: INTRODUCTION
Lack of physical activity (PA) is a global public health problem.1 While
nearly half of U.S. adults are not meeting PA guidelines,2 for adults living with
movement disability the prevalence of inactivity is even higher.3 Of the nearly
930,000 U.S. adults with Parkinson’s disease (PD),4 only 27% are meeting PA
guidelines5 and of the 6.8 million people in the U.S. with stroke,6 only 18% are
meeting PA guidelines.7 High levels of inactivity for people with PD (pwPD) and
stroke is a substantial problem as both groups are at a heightened risk for
cardiovascular disease, further disability and premature death,8–12 all of which
can be mitigated through performing adequate amounts of PA.
Various modes of PA have proven health benefits for pwPD and stroke.
Walking, in particular, has been shown to improve walking speed,13
cardiorespiratory fitness,13–15 fatigue, depression, quality of life and slow disease
progression15 in pwPD. Similarly, for individuals with stroke, walking interventions
have led to improvements in walking speed,16 walking endurance17 and
cardiorespiratory fitnesss.18 Walking as a mode of PA is also strongly
recommended by the U.S. surgeon general19 and the 2018 PA Guidelines for
Americans, which state that individuals with chronic health conditions should
perform at least 150 weekly minutes of moderate-intensity aerobic PA.20
Unfortunately, these guidelines are not being met by the majority of pwPD or
stroke and alternative methods to increase PA (e.g. by promoting increased daily
1

steps) are warranted. One limitation with current guidelines is that measuring and
tracking PA intensity requires individuals to assess intensity through heart rate,
respiratory rate, perceived effort, or speed (among others), which may be difficult
for individuals with cognitive impairment from PD or stroke. Daily step counts, on
the other hand, provide users with a single metric that is easy to understand and
can be used to set goals and track individual progress. In addition, daily steps
can be measured relatively inexpensively and accurately using commercially
available wearables.5,21–23
While current PA guidelines recommend walking, they do not endorse a
specific daily step count and research involving clinical populations is sparce.
Previous research has suggested 7000 to 1000024 steps per day is appropriate
for healthy older adults to achieve health benefits through walking. PwPD and
stroke, however, often have walking impairments,25,26 making these
recommendations unrealistic and unobtainable.27,28 For example, pwPD take
2300 less steps than their age-matched peers27 and daily steps decrease as the
disease progresses.29,30 People with stroke may walk even less, averaging 4000
fewer steps per day compared to healthy adults.28 While higher levels of PA (or
steps) provide additional health benefits, lower levels may still be beneficial. Lee
et al31 examined nearly 17,000 older women (mean age=72 years) across four
years and found that just 4400 steps per day was related to a 41% decrease in
mortality rates compared to 2700 steps per day. Additionally, mortality rates
continued to decrease until reaching a plateau at 7500 steps per day.
Interestingly, the authors found that after adjusting for daily step count, the
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importance of step intensity was reduced, which led the authors to conclude that
daily step counts may be of greater value than metrics of intensity.
Overall, there is little evidence to guide daily step recommendations for
those with PD or stroke. Additionally, few interventions to date have successfully
increased daily steps in these populations.14,16,32,33 Therefore, using two large
and publicly available datasets, the purpose of the following two studies was to
identify daily step counts associated with health outcomes and provide data that
can be used to inform future interventions aimed at improving PA in those with
PD or stroke. Specifically, for people with PD (Chapter 2), there were three
questions targeted:
1) What daily step threshold corresponded to meeting PA guidelines?
2) For those below the determined daily step threshold, what were the
effects of treadmill exercise performed at varying intensities on daily steps
and moderate-to-vigorous intensity PA (MVPA)?
3) For those below the determined daily step threshold, what was the
relationship between changes in daily steps and cardiorespiratory fitness?
For people with stroke (Chapter 3), there were two aims:
1) Determine which factors (both nonmodifiable and modifiable) present at
two months post-stroke can predict daily step counts at one year poststroke.
2) Determine a daily step threshold at two months post stroke that
corresponds to obtaining >6000 daily steps at one year post-stroke.
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CHAPTER 2: PHYSICAL ACTIVITY IN DE NOVO PARKINSON’S
DISEASE: DAILY STEP RECOMMENDATION AND EFFECTS OF
TREADMILL EXERCISE ON PHYSICAL ACTIVITY
INTRODUCTION
Parkinson’s disease (PD) is a progressive degenerative neurological
disease that reduces function, independence, and quality of life for millions of
people around the world.34 Physical activity (PA) and more specifically walking,
has been shown to improve walking speed,13 cardiorespiratory fitness,13–15
fatigue, depression, quality of life and slow disease progression.15 Walking is also
strongly recommended by the U.S. surgeon general19 and the 2018 PA
Guidelines for Americans.20 Unfortunately, people living with PD are 29% less
physically active than those without,35 and, as the disease progresses, daily step
counts and PA levels also decrease.29,30 Therefore, there is an urgent need for
interventions aimed at increasing PA levels in pwPD.
Steps are an appealing method of objectively measuring PA in pwPD
given they can easily be captured and displayed using inexpensive commercially
available wearables. Additionally, because nearly one third of people newly
diagnosed with PD exhibit mild cognitive impairment,36 steps may be an
especially preferential PA target as they provide a single and simple metric to
comprehend and track. While 7,000 to 10,00024 daily steps has been suggested
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as the number needed to meet PA guidelines in healthy older adults, there is no
current step recommendation for those with PD and the relationship between
steps and other established health outcomes such as cardiorespiratory fitness37
is unclear.
Most research regarding step counts in pwPD has been from cross
sectional assessments.5,27,38–40 To date, few interventions have examined
changes in daily steps in pwPD. Two recent randomized controlled trials which
used walking for exercise as the intervention found no significant changes in
daily steps.14,33 These null findings are of interest, especially considering that
both interventions recruited individuals who reported not being regular exercisers
prior to study onset. In the Study in Parkinson’s Disease of Exercise (SPARX)
trial,14,41 which had two exercise groups and one control group, authors
suggested that those in the exercise groups may have reduced the number of
steps taken outside the intervention so that average daily steps remained
unchanged. While this may have been true when considering the entire sample,
what about the individuals who were the least active? Would they see meaningful
improvements in steps, PA, and/or other health outcomes as a result of the
exercise intervention?
Using data from the SPARX trial, the present study examined the effects
of treadmill exercise on PA levels in people with de novo PD. We analyzed the
least active participants, as these individuals arguably have the most to gain (in
terms of health benefits) from increasing PA. Specifically, there were three aims:
1) What daily step threshold corresponded to meeting PA guidelines? 2) For
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those below the determined daily step threshold, what were the effects of
treadmill exercise performed at varying intensities on daily steps and moderateto-vigorous intensity PA (MVPA)? 3) For those below the determined daily step
threshold, what was the relationship between changes in daily steps and
cardiorespiratory fitness?
METHODS
Study Design and Participants
This research is based on a deidentified dataset obtained from the
National Institute of Neurologic Disease and Stroke’s (NINDS) Archived Clinical
Research data (Study in Parkinson’s Disease of Exercise [SPARX], Margaret
Schenkman, PT, PhD, NCT01506479) received from the Archived Clinical
Research Dataset website. The SPARX trial was a multicenter, randomized,
controlled, single-assessor-blinded, Phase II study.41 Participants with de novo
PD were randomized to one of three groups: high-intensity treadmill exercise (8085% maximum heart rate [HRmax]), moderate-intensity treadmill exercise (6065% HRmax) or a waitlist control who received usual care. All participants from
the SPARX trial provided informed consent and the study was approved by
associated institutional review boards.14 The present secondary analysis
received exemption from the University of South Carolina’s institutional review
board.
Recruitment procedures, inclusion and exclusion criteria for the SPARX
trial have previously been described.14,41 In summary, included participants were
between the ages of 40 and 80 years, with idiopathic PD, Hoehn and Yahr stage
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less than III and who were in the early stages of PD and naïve to therapy (also
known as de novo).42–44 Individuals were excluded if they were currently being
treated pharmacologically for PD, unable to perform high-intensity exercise or if
they reported regularly (>2 days/week for > 4 months) participating in moderate
to vigorous aerobic exercise. To be included in the present study, participants
were required to have step data at baseline (i.e. before intervention) for aim one,
step or VO2peak data at baseline and at five and/or six months for aim two and
both step data and VO2peak data at baseline and at five and/or six months for
aim three. A flow diagram demonstrating how participant data were utilized is
displayed in Figure 1.
Treadmill Exercise Intervention & Waitlist Control Group
Both high-intensity and moderate-intensity exercise groups were
prescribed the same mode, frequency and duration of exercise, which was
treadmill exercise (i.e. walking) performed 4 days/week for 26 weeks with 45
minute sessions.14 Frequency and intensity of exercise were gradually increased
for the first 8 weeks of the intervention until target HR levels were reached.
Treadmill speed and/or incline was adjusted to maintain target HR. Both high and
moderate-intensity exercise groups met the prescribed exercise intensities and
frequencies over the six month intervention, demonstrating intervention fidelity. 14
Those in the waitlist control group were instructed to continue their regular
behavior.
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Participant Descriptors
Participant age, sex, time since Parkinson’s disease diagnosis, Movement
Disorder Society-Unified Parkinson Disease Rating Scale (MDS-UPDRS) motor
score (part III),45 item 9 on the Parkinson’s Disease Questionnaire - 39 (PDQ39)46 and the presence or absence of a cardiovascular health condition (e.g.
hypertension) were used to describe the sample. Previous literature found these
factors to be significant explanatory variables for daily steps, with higher daily
step counts associated with less time since diagnosis, lower MDS-UPDRS motor
scores, no reported fear or worry of falling (Item 9 of the PDQ-39) and the
presence of a cardiovascular condition.37
Activity Monitoring
To capture PA (steps and activity counts), participants were instructed to
don a waist-worn Actigraph GT3X [+ and BT]; Actigraph, Pensacola, Florida)
during waking hours over a 10-day period, once a month for the duration of the
six month (26 week) intervention.37,41 The activity monitors have demonstrated
moderate to high validity and reliability in assessment of free-living activity47–49
and steps in pwPD.5,21 Steps and activity counts were summed over each 60
second epoch and then averaged over total monitor wear time. With the 3-axis
activity monitor, steps are based on vertical axis acceleration whereas activity
counts are based on acceleration in all 3-axes and reflect the frequency and
intensity of movement.37 Activity counts per minute of wear time were used to
classify activity as sedentary (<100 counts/min), light (100-1951 counts/min),
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moderate (1952-5724 counts/min) and vigorous (>5725 counts/min) intensity
PA.50,51
Valid activity monitoring days were considered those with at least 10 hours
of valid wear time and a maximum of 90 minutes of non-wear time.37,52 For each
assessment point (i.e. baseline and five and/or six months) participants needed
at least four valid days to be included in the analysis. To examine the effect of
treadmill exercise on average daily step counts (aim two), participants in the two
exercise groups (i.e. high and moderate intensity treadmill exercise) were
required to have at least two treadmill exercise session in which steps (and
activity counts) were recorded. If activity data were available at both five and six
months, these data were averaged, whereas if data were only available for one
of these timepoints, these data were used. We chose to examine activity data at
five and/or six months when present as it was postulated that this would
represent the peak activity levels during the progressive six month intervention.
Cardiorespiratory Fitness
Assessment of cardiorespiratory fitness was performed at baseline and at
six months via a maximal graded exercise test (treadmill walking) with
assessment of VO2peak (mL/min/kg) by indirect calorimetry and HRmax.37,41
Treadmill walking speed was adjusted so that participants were exercising at
70% of their age-predicted maximum heart rate. Participants using chronotropic
medications walked at a speed that corresponded to a 4 out of 10 on the
modified Borg Rating of Perceived Exertion scale.53,54
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Data Analysis
Descriptive statistics were calculated for all participants with valid baseline
step data. The Shapiro-Wilk test was used to assess all data for normality.55
Using baseline (prior to intervention) activity data, participants were first
categorized as “meeting” or “not meeting” aerobic PA guidelines, which states
individuals should perform >150 weekly minutes of moderate intensity aerobic
PA.20 Average daily activity minutes (measured via activity monitor) performed at
a moderate intensity or greater was multiplied by seven for an estimate of weekly
PA for each participant. Accumulation of vigorous activity was low (less than one
second per hour for those not meeting guidelines) and therefore was combined
to form MVPA.5 To determine the diagnostic accuracy of average daily step
count and VO2peak (independent variables) to correctly classify those who meet
PA guidelines (dependent variable), receiver operating characteristic (ROC)
curves, including the area under the curve (AUC), were generated.56 Sensitivity,
specificity, likelihood ratios and Youden’s index (J)57 were also calculated. The
single highest J value was chosen as the optimal threshold58 to accurately
classify participants as “meeting” or “not meeting” PA guidelines (i.e. >150 or
<150 minutes of at least moderate-intensity PA). Based on the determined step
threshold, participants were dichotomized into two step groups (i.e. participants
above and below the step threshold), with participant descriptors and PA
variables (e.g. steps, moderate intensity PA) compared with independent t-tests
or Mann-Whitney U tests, and chi-squared tests.
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A comparison within and between subjects was made for participants
below the determined step threshold in each of the three SPARX groups (i.e.
high-intensity exercise, moderate-intensity exercise and waitlist control). Three
separate Mixed-Design Two-Way Repeated Measures Analysis of Variance
identified differences in the dependent variables of daily steps, MVPA and
VO2peak between assessment points (baseline and five and/or six months),
groups, and/or the interaction between time and group. A Bonferroni adjustment
was applied to control for multiple comparisons. Post-hoc tests (i.e. t-tests or one
way analysis of variance) were performed and effect sizes (Cohen’s d) were then
calculated to determine the effects of treadmill exercise performed at varying
intensities on PA. Effect sizes of 0.8 were considered large, 0.5 were considered
medium and 0.2 were considered small.59 The relationship between changes in
daily steps and VO2peak were examined using Pearson’s r correlations.
Alpha level was set at <.05 for all statistical tests, and all analyses were
performed using IBM SPSS Statistics for Macintosh, Version 26.0 (IBM SPSS,
Chicago, IL, USA).
RESULTS
Step threshold that corresponds to meeting aerobic PA guidelines
Of the 110 participants with valid PA data at baseline (Figure 1), 84
(76.4%) had > 150 weekly minutes of MVPA and thus met aerobic PA guidelines
(Table 1). ROC curves are displayed in Figure 2. Resulting thresholds that
corresponded to meeting aerobic PA guidelines were 4197 daily steps and a
VO2peak of 23.9mL/min/kg. Corresponding AUC are displayed in Table 2. The
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threshold of 4197 daily steps correctly classified 87% (sensitivity) of participants
who met/exceeded PA guidelines and 96% (specificity) of people who did not
meet PA guidelines. A comparison of participants with >4200 and <4200 daily
steps is displayed in Table 1. Those averaging <4200 daily steps were older,
more likely to report a fear of falling and had lower baseline fitness levels.
Effects of treadmill exercise performed at varying intensities on PA
Of the 36 participants with an average of <4200 daily steps, 33 had the
appropriate data and were analyzed (Figure 1). Descriptive baseline data for the
33 participants, including group allocation are displayed (Table 3). At five and/or
six months, 85.7% (12/14), 33.3% (2/6) and 23.1% (3/13) of participants met PA
guidelines in the high-intensity, moderate-intensity and waitlist control groups,
respectively (data not in table).
At five and/or six months, participants in the high intensity group (n=14)
had a median of 5.5 (2, 11) treadmill exercise sessions with activity monitoring
and averaged 2604 (1283) steps per session, whereas those in the moderate
intensity group (n=6) had a median of 7.5 (2, 9) treadmill exercise sessions with
activity monitoring and averaged 1809 (1418) steps; neither number of exercise
sessions with activity monitoring nor average steps were statistically different
(p=0.54 and p=0.23, respectively). Average daily activity monitor wear time at
five and/or six months was not significantly different between the three groups
(p=0.60; high-intensity group 817 (138), moderate-intensity group 765 (99) and
waitlist control 795 (114) minutes per day). Analysis of daily steps revealed a
main effect for time (p=0.03), with no main effect for group (p=0.14) nor
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time*group interaction (p=0.10, Figure 3). Subsequent paired t-tests revealed that
the high-intensity group significantly increased daily steps by 1220 (1614) steps
(p=.01, 95% CI 288 to 2152) whereas within group differences in steps for the
moderate-intensity group and the waitlist control group did not reach statistical
significance: 435 (845) steps (p=.26, 95% CI -452 to 1322) and 85 (1207) steps
(p=.80, 95% CI -644 to 815, respectively). Within group effect sizes (Cohen’s d)
for changes in average daily steps were 0.98, 0.52 and 0.08 for high intensity,
moderate intensity and waitlist control groups, respectively.
For MVPA, there was a main effect for time (p=0.01) and group (p=0.02)
but no statistically significant time*group interaction (p=.16, Figure 3). Post-hoc
paired t tests revealed an average daily MVPA increase of 13 (14.6) minutes for
the high intensity group (p=0.01, 95% CI 4.8 to 21.2) but no change for moderate
intensity 5.1 (10.2) minutes (p=0.27, 95% CI -5.6 to 15.80) or waitlist control 3.7
(12.5) (p = 0.31, 95% CI -3.8 to 11.2). Within group effect sizes for changes in
average daily MVPA were 0.91, 0.48 and 0.30 for high intensity, moderate
intensity and waitlist control groups, respectively. Between group comparisons
using independent t-tests showed that MVPA at five and/or six months was
higher in the high intensity group compared to both the moderate intensity group
(mean difference = 14.5 minutes, p= 0.04, 95% CI .41 to 28.7) and waitlist control
(mean difference = 17.4 minutes, p=0.01, 95% CI 5.7 to 29.1). The moderate
intensity group obtained higher levels of MVPA compared to waitlist control but
the difference was not statistically significant (mean difference = 2.9 minutes,
p=0.70, 95% CI -12.5 to 18.2).
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Relationship between changes in daily steps and fitness
For changes in VO2peak, there were no significant main effects for time
(p=0.81) or group (p=.94); however, a group*time interaction was present
(p=0.03, Figure 3). A post-hoc one way analysis of variance revealed no
significant between-group differences in VO2peak at six months (p=0.91). Within
group effect sizes (Cohen’s d) for changes in VO2peak were 0.23, 0.10 and -0.44
for high intensity, moderate intensity and waitlist control groups, respectively.
Changes in daily steps were not significantly associated with changes in
VO2peak (r=.183, p=0.16)
DISCUSSION
What daily step threshold corresponds to meeting PA guidelines?
Using the 4200 steps per day threshold correctly classified 87% of
participants who met PA guidelines and 96% of participants who did not. In other
words, those obtaining >4200 steps were 23 times more likely to meet PA
guidelines compared to those with <4200 steps. At face value, 4200 daily steps
may appear low, especially compared to the popular 10,000 steps per day60 or
the frequently cited 7,000 steps per day thresholds.61,62 The aforementioned
thresholds, however, are geared towards healthy adults. For people with
disability, there is limited evidence supporting a daily step recommendation24 but
our value of 4200 daily steps may provide a starting point. Lee et al.31 found that
just 4400 steps per day was related to a decrease in mortality rate in older
women. In addition, Lee et al.31 found that after adjusting for daily step count, the
importance of step intensity was reduced, leading authors to conclude that daily
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step counts may be of greater value than metrics of intensity. Because
Parkinson’s adversely impacts both cognition and mobility, setting a goal of 4200
daily steps may be a more obtainable target for pwPD as compared to
assessment of time spent in moderate-intensity PA. To provide further support
for the recommendation of 4200 daily steps, future longitudinal studies should
examine the relationship between 4200 daily steps, mortality and other PDspecific outcomes.
Out of 110 participants at baseline (i.e. before intervention), over 75% met
PA guidelines. Our highly active sample is in contrast to the 27% of participants
who met PA guidelines in a recent study (n=95).5 Differences found between the
two studies may be due to differences in participant age (mean age of 73 versus
our median of 65 years) and disease severity (H&Y II and III versus <III in the
present study). Furthermore, though the same activity monitor (ActiGraph
GT3X+) was used, the present study utilized a slightly lower cutoff (i.e. 1,952 vs.
2,019 counts per minute5) to classify moderate intensity PA and thus the number
of participants meeting PA guidelines in the present study may have been
inflated. Because the SPARX trial consisted of a rigorous six month exercise
intervention, our participants may represent a more active group of pwPD.
Interestingly, participants who reported performance of moderate-to-vigorous
aerobic exercise more than twice per week for the last four months were
excluded from the SPARX trial. The fact that our sample was highly active at
baseline as measured by activity monitor, reiterates the known discrepancies
between PA assessed by self-report and activity monitors.38,63 Alternatively,
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participants may not have been regular exercisers prior to their diagnosis. With a
median time since diagnosis of less than one year, participants may have
become physically active only after receiving their PD diagnosis, which could
have been within the four months prior to beginning the SPARX trial. Though
MVPA was higher in the current study, daily step counts (4817) were similar to
previous studies (3615 to 5452)5,27,38 but also lower than others (8686 to
10,261).30,33,39 Participants in the present study may have accumulated MVPA in
relatively few bouts, with minimal stepping activity for the remainder of the day.
For those with <4200 daily steps, what are the effects of treadmill exercise
performed at varying intensities on PA?
Participants with less than 4200 steps at baseline who engaged in highintensity treadmill exercise observed a large and significant increase in daily
minutes spent performing MVPA. For pwPD, the benefits of MVPA are well
established and include improvements in cardiorespiratory fitness,14,15 fatigue,
depression, quality of life and slowing of disease progression.14,15 For older
adults, replacing 10 minutes of sedentary time with 10 minutes of MVPA led to a
21% risk reduction in mortality.64 While the smallest amount of MVPA required to
see PD-specific benefits has yet to be determined, current PA guidelines clearly
state that any amount of MVPA is beneficial to health.20 Thus, when interpreting
changes in MVPA, especially in those with the lowest activity levels, researchers
should be encouraged to look at the magnitude of change, rather than just
statistical significance, to ensure meaningful gains in MVPA are captured.
Though our findings suggest that high-intensity exercise may be superior to
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moderate-intensity exercise in terms of accumulating MVPA, other factors such
as participant preference and capability must also be considered when
prescribing exercise regimens.
Participants with less than 4200 steps at baseline who were in the highintensity exercise group also observed a large and significant increase in daily
steps (1220, 95% CI 288 to 2152). While there is no available minimally clinically
important difference (MCID) for daily step counts in pwPD, in individuals with
Multiple sclerosis, a change of 800 steps per day reflected changes in participant
reported walking ability.65 For adults at risk for type 2 diabetes, an increase of
2000 daily steps was associated with reduced cardiovascular events.66 This last
finding is pertinent, as pwPD are at greater risk for development of
cardiovascular disease,10,11 which is responsible for nearly one in five deaths in
those with PD.12 While only participants in the high-intensity exercise group had
significant increases in daily steps, there was a medium within group effect size
for the moderate-intensity exercise group and a miniscule effect size for the
control group. Though no significant between group differences in daily steps
were found, this may have been a result of the small number of participants in
each group. Overall, our results imply that treadmill exercise of any intensity may
be enough to make positive changes in daily step counts.
For those with <4200 daily steps, what is the relationship between changes in
daily steps and cardiorespiratory fitness?
In a cross-sectional analysis of the same sample as the present study,
Christiansen et al.37 found that cardiorespiratory fitness (VO2peak) explained the
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largest amount of variability (10%) in daily step counts. Using the longitudinal
data from the SPARX trial, the present study found that changes in daily step
counts were not significantly associated with changes in VO2peak. This finding is
not surprising given the lack of significant changes found in VO2peak amongst
those with <4200 daily steps. While linking step counts to a powerful health
outcome such as cardiorespiratory fitness would be welcome, the two metrics
may provide meaningful but unique information. Cardiorespiratory fitness, which
is considered a clinical vital sign,67 is largely determined by genetics.68 Genetics
also determines up to 50% of an individual’s response to exercise training. 69 On
the other hand, daily steps are more fluid and vary based on age, gender,
walking ability, and disease severity,70 as well as other factors such as weather,71
motivation72 and the physical environment.73 Another possible explanation for the
lack of a significant association could be due to the fact that steps counts do not
provide information on intensity. For the least active participants in our sample,
obtaining MVPA outside of exercise sessions may have been difficult and thus
daily steps may have been performed predominantly as light-intensity PA. If the
majority of steps were of light-intensity, changes in cardiorespiratory fitness
would likely be minimal. For these individuals, increasing light, rather than MVPA,
may be more feasible.74 The role light-intensity PA plays in health outcomes is
becomingly increasingly apparent and future research examining light-intensity
PA may help inform guidelines that include more than just MVPA
recommendations.75
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Limitations
Strengths of the present study include calculation of a sample-specific
step threshold to classify those who meet PA guidelines and analysis of pwPD
with the lowest PA levels (i.e. steps). Nevertheless, the study has several
limitations. Calculation of the 4200 steps per day threshold relied on two metrics
(steps and minutes spent in MVPA) which were both derived from the same
activity monitor. Use of different cutpoints to define MVPA would likely yield a
different step threshold. As a retrospective study, no power analysis was
conducted and could explain lack of significant findings between the two exercise
groups and the waitlist control group. In addition, only 33 participants had <4200
daily steps at baseline and sample sizes became even smaller when comparing
groups (i.e. high-intensity, moderate-intensity, waitlist control). Finally, the activity
monitor cutpoints used to classify sedentary behavior, light-intensity PA and
MVPA were derived from studies in healthy adults and may not be ideal for
people with physical impariments.76 Cutpoints to accurately determine PA
intensity vary by age,77 activity being performed78 and walking speed.79
Researchers must consider these factors when choosing appropriate cutpoints
for their sample.
CONCLUSION
The present study determined that for people with de novo PD, 4200 daily
steps corresponded to meeting PA guidelines. In addition, for those with <4200
daily steps, high-intensity treadmill exercise led to increases in daily steps and
MVPA, though these gains were not associated with changes in cardiorespiratory
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fitness. Collectively, our results have important research and clinical implications.
The least active participants at baseline in both exercise groups outperformed (in
terms of effect size) the waitlist control group in terms of steps and MVPA. For
clinicians working with patients recently diagnosed with PD, the 4200 steps per
day threshold may be used, albeit cautiously, to infer whether or not PA
guidelines are being met. While the true value of daily step counts is still being
determined, the present study provides new information on the relationship
between steps and health, and provides evidence supporting exercise as a tool
to increase PA in people with de novo PD. Additional work is needed to
determine the best means of maintaining and continuing to improve both PA and
health in pwPD.
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Table 2.1 Pre-Randomized Baseline Descriptors of Participantsa

> 4200

< 4200

Participants

Steps/day

Steps/day

(n=110)

(n=74)

(n=36)

P

65 (40, 80)

61.5 (39, 79)

70.5 (48, 80)

<0.001b

48 (43.6)

29 (39.2)

19 (52.8)

0.18c

0 (0, 5)

0 (0, 5)

1 (0, 4)

0.10b

19 (5, 60)

18.5 (7, 39)

22 (5, 60)

0.06b

(PDQ-39, Item 9)e

77 (70)

61 (82.4)

16 (44.4)

Never, n (%)

33 (30)

13 (17.6)

20 (55.6)

52 (47.3)

39 (52.7)

13 (36.1)

22.8

24.1

20.9

Descriptor
Age, years
Female, n (%)
Time since PD
diagnosis, years
MDS-UPDRS
motor score

(III)d

Fear/worry of falling
<0.001c

Any, n (%)
Cardiovascular
condition present, n

0.10c

(%)
VO2peak,
mL/min/kg

(9.2,

43.7)f

(13.1, 43.7)

(9.2,

33.3)f

<0.001b

Sedentary activity,
min/hr wear time,

33.5 (6.1)

32.3 (6.3)

36 (4.8)

0.75g

23.3 (5.5)

23.5 (5.8)

22.9 (5.0)

0.21g

2.8 (0.1, 9.5)

3.5 (1.3, 9.5)

0.8 (0.1, 3.4)

<0.001b

36.8

49

11.1

(0.8, 131.1)

(19.7, 131.1)

(0.8, 45.3)

mean (SD)
Light activity,
min/hr wear time,
mean (SD)
MVPA, min/hr wear
time
Total daily MVPA,
min
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<0.001b

Meets aerobic PA
guidelines, n

(%)h

Steps per day

84 (76.4)

4817
(763, 15802)

Monitor wear time,
min, mean (SD)

809 (87)

73 (98.6)
6066
(4202,
15802)
809 (83)

11 (30.6)

2852
(763, 4192)

810 (94)

<0.001c

<0.001b

0.94g

Abbreviations: PD, Parkinson’s disease; MDS-UPDRS, Movement Disorder
Society-Unified Parkinson’s Disease Rating Scale; PDQ-39, Parkinson’s Disease
Questionaire-39, VO2peak, maximal rate of oxygen consumption during maximal
graded exercise test, measured in milliliters (mL) per minute (min) per kilogram
(kg) of body mass; min/hr, minutes per hour; MVPA, moderate-to-vigorous
intensity physical activity; PA, physical activity
a Data presented as median (minimum, maximum) unless otherwise stated.
Physical activity intensity classified as sedentary (<100 counts/min), light (1001951 counts/min), moderate (1952-5724 counts/min) and vigorous (>5725
counts/min).50,51 Boldface indicates significant at p <0.05.
b Independent samples, Mann-Whitney U test.
c Pearson Chi-Square, 2-sided
d The MDS-UPDRS motor score (part III) consists of 33 items including but not
limited to assessment of speech, upper and lower extremity coordination, sit to
stand ability and gait. Examiners rate participants on a five pinot scale ranging
from 0 (normal) to 4 (severe) with higher scores indicating greater disease
severity.45
e Item 9 of the PDQ-39 asks participants, “Due to having Parkinson’s disease,
how often during the last month have you felt frightened or worried about falling
over in public?” Participants respond via five-point Likert scale ranging from
“never” to “always.”46 The present study followed previously reported methods37
and dichotomized responses to item 9 by considering any response other than
“never” as having fear or worry about falling present.
f VO2peak data was missing from one participant (n=109) in the <4200 steps/day
group (n=35)
g Independent samples t-test, 2-sided
h Physical activity guidelines are from the U.S. Department of Health and Human
Services which recommend adults participate in at least 150 minutes of
moderate-intensity physical activity each week.20
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Table 2.2 Accuracy of Daily Step Count and VO2peak to Classify People with
Parkinson’s Disease as Meeting or Not Meeting Aerobic Physical Activity
Guidelinesa

AUCb
Thresholds

(95% CI)

Daily Steps

0.95

4,197

(.90 to 1.00)

Sensitivity

87%

Specificity

96%

VO2peak

+LR

-LR

(95% CI)

(95% CI)
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0.14

(7.72 to

(.05 to

68)

0.37)

6.55

0.52

(1.74 to

(.40 to

25)

0.67)

.76
(mL/min/kg)

52%

92%

(.66 to .85)
23.9

Abbreviations: AUC, area under the receiver operating characteristics curve;
95% CI, 95% confidence interval; VO2peak, maximal rate of oxygen
consumption during maximal graded exercise test, measured in milliliters (mL)
per minute (min) per kilogram (kg) of body mass; +LR, positive likelihood ratio; LR, negative likelihood ratio
a Physical activity guidelines are from the U.S. Department of Health and Human
Services which recommend adults participate in at least 150 minutes of
moderate-intensity physical activity each week.20 Using the daily step count
threshold of 4197 steps correctly classified 87% (sensitivity) of participants who
met/exceeded 150 minutes of MVPA and 96% (specificity) of participants who did
not meet guidelines. Participants meeting/exceeding aerobic physical activity
guidelines were between 7.72 and 68 times more likely to have at least 4200
steps compared to those not meeting guidelines. Boldface indicates significant at
p <0.001.
b An AUC value of 1.0 indicates a perfect diagnostic test, whereas an AUC of 0.5
is equal to chance (i.e. the test has no value).
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Table 2.3 Baseline Descriptors For Participants with <4200 Daily Stepsa

Descriptor
Age, years
Female, n (%)

High

Moderate

Waitlist

Participants

Intensity

Intensity

Control

(n=33)

(n=14)

(n=6)

(N=13)

73 (48,

69 (54,

71 (57,

77)

80)

76)

17 (51.5)

10 (71.4)

2 (33.3)

5 (38.5)

0.14c

1 (0, 4)

1 (0, 3)

1 (0, 2)

1 (0, 4)

0.73b

22

23.5

17.5

22

(5, 60)

(5, 34)

(16, 36)

(12, 60)

15(45.5)

5(35.7)

2(33.3)

8(61.5)

18 (54.5)

9(64.3)

4(66.7)

5(38.5)

11 (33.3)

5 (35.7)

4 (66.7)

2 (15.4)

71 (48, 80)

P
0.94b

Time since PD
diagnosis,
years
MDS-UPDRS
motor score
(III)

0.99b

Fear/worry of
falling (PDQ39, Item 9)c
Never (%)

0.33c

Any (%)
Cardiovascular
condition

0.09c

present, n (%)
VO2peak,
mL/min/kg

21.4
(15.7, 33.3)

18.8
(15.7,
33.3)d

22.1
(16.5, 25)

22
(16.2,

0.54b

28)d

Sedentary
activity, min/hr
wear time,

35.7(4.8)

35 (6.1)

35.9 (3.2)

23.2 (5.1)

23.5 (6.5)

23.2 (3.6)

36.4
(4.0)

0.77e

mean (SD)
Light activity,
min/hr wear
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22.8
(4.1)

0.93e

MVPA, min/hr
wear time,

1.1 (0.8)

1.5 (1.0)

1(0.6)

0.9 (0.6)

0.17e

mean (SD)
Total daily
MVPA, min,

15.5 (11.7)

mean (SD)

19.9
(14.6)

13.2 (7.4)

11.8
(8.5)

0.18e

Meets aerobic
PA guidelines,

10 (30.3)

7 (50)

1 (16.7)

2 (15.4)

2904

3218

2795

(943)

(547)

(745)

813 (127)

798 (29)

821 (80)

0.11c

n (%)f
Steps per day,
mean (SD)

2918 (799)

0.58e

Monitor wear
time, min,

813 (95)

0.89e

mean (SD)
Abbreviations: PD, Parkinson’s disease; PDQ-39, MDS-UPDRS, Movement
Disorder Society-Unified Parkinson’s Disease Rating Scale; Parkinson’s Disease
Questionaire-39, VO2peak, maximal rate of oxygen consumption during maximal
graded exercise test, measured in milliliters (mL) per minute (min) per kilogram
(kg) of body mass; min/hr, minutes per hour; MVPA, moderate-to-vigorous
intensity physical activity; PA, physical activity
a Data presented as median (minimum, maximum) unless otherwise stated.
Physical activity intensity classified as sedentary (<100 counts/min), light (1001951 counts/min), moderate (1952-5724 counts/min) and vigorous (>5725
counts/min)
b Kruskal–Wallis one-way analysis of variance
c Pearson Chi-Square, 2-sided;
d VO2peak data was missing from two participants (n=31) with one from highintensity group (n=13) and one from waitlist control group (n=12)
e One-way analysis of variance
f Physical activity guidelines are from the U.S. Department of Health and Human
Services which recommend adults participate in at least 150 minutes of
moderate-intensity physical activity each week.20
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Aim One

Participants with step data
received from NINDS dataset
N = 115
Excluded participants with reasons
n = 5 – less than four valid days with step data
Participants analyzed
N = 110

Aim Two

Participants with <4200 daily steps
on average
N = 36
Excluded participants with reasons
n = 2 – no exercise step data
n = 1 – less than four valid days with step data
Participants analyzed for
differences in steps & MVPA
N = 33
High-intensity group (n=14)
Moderate-intensity group (n=6)
Waitlist control group (n=13)

Aims Two & Three

Excluded participants with reasons
n = 1 – no VO2peak data at baseline
n = 1 – no VO2peak data at six months
Participants analyzed for
differences in VO2peak & changes
in daily steps & VO2peak
N = 31
High-intensity group (n=13)
Moderate-intensity group (n=6)
Waitlist control group (n=12)

Figure 2.1 Flow Diagram of Participant Data
Abbreviations: NINDS, National Institute of Neurologic Disorders and Stroke;
MVPA, moderate-to-vigorous intensity physical activity; VO2peak, maximal rate
of oxygen consumption during maximal graded exercise test, measured in
milliliters per minute per kilogram of body mass
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Figure 2.2 Receiver Operating Characteristics Curves for Average Daily Steps
and VO2peak to Classify People with Parkinson’s Disease as Meeting or Not
Meeting Aerobic Physical Activity Guidelinesa
Abbreviations: VO2peak, maximal rate of oxygen consumption during maximal
graded exercise test, measured in milliliters (mL) per minute (min) per kilogram
(kg) of body mass;
a Physical activity guidelines are from the U.S. Department of Health and Human
Services which recommend adults participate in at least 150 minutes of
moderate-intensity physical activity each week.20 Dashed reference line indicates
a test that randomly classifies a condition (i.e. a test with 50% accuracy).
b Optimal daily step threshold found in the present study
c Optimal VO2peak threshold found in the present study
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A
5000

P=.01

Average Daily Steps
(Steps/day)

4500
4000
3500
3000
2500
2000

High-Intensity
(n=14)

Moderate-Intensity Waitlist Control
(n=6)
(n=13)

P=.01

B
45

P=.04
P=.01

40
Average Daily MVPA
(Minutes/day)

35
30

Assessment

25

Baseline

20

Five and/or Six Months

15
10
5
0

C

High-Intensity
(n=14)

Moderate-Intensity
(n=6)

Waitlist Control
(n=13)

High-Intensity
(n=13)

Moderate-Intensity
(n=6)

Waitlist Control
(n=12)

26

Average VO2peak
(mL/min/kg)

24
22
20
18
16
14

Figure 2.3 Within and Between Group Comparison of A) Average Daily Steps, B)
Average Daily MVPA, C) Average VO2peaka
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Abbreviations: MVPA, moderate-to-vigorous intensity physical activity; VO2peak,
maximal rate of oxygen consumption during maximal graded exercise test,
measured in milliliters (mL) per minute (min) per kilogram (kg) of body mass.
a Data presented as means with vertical black bars indicating 95% Confidence
Intervals. For all dependent variables (steps, MVPA, VO2peak), groups were not
statistically different at baseline.
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CHAPTER 3: DAILY STEP COUNT AND BALANCE AT TWO
MONTHS POST-STROKE ARE THE STRONGEST PREDICTORS
OF DAILY STEPS AT ONE YEAR POST-STROKE
INTRODUCTION
Improving walking ability is a predominant goal for people after stroke.80
Not surprisingly, rehabilitation primarily focuses on regaining and improving
walking ability.81 While components of walking, including speed and endurance,
have been heavily researched and shown to improve in response to
interventions,16,18,82 there has recently been an increased interest in free-living
walking behavior, as measured by daily step counts.23,32,40,83 Unlike walking
speed or endurance, daily steps are thought to represent participation outside the
clinical environment and thus offer a unique insight into physical activity (PA) and
walking behavior.82,84 Daily steps may even predict future health outcomes, with
attainment of >6000 steps related to a decreased risk for subsequent
cardiovascular disease in adults with stroke.85 Decreasing risk in adults with
stroke is paramount considering nearly one in four survivors will experience a
second stroke,86 which is often more debilitating and deadly than their initial
stroke.8,87
Examination of what contributes to daily steps after stroke is needed in
order to inform interventions aimed at increasing PA through walking. A 2018
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meta-analysis88 examined correlates of PA (including daily steps) in people with
stroke and found that the modifiable factors of physical function, cardiorespiratory
fitness, fatigue, falls and balance self-efficacy, depression and health-related
quality of life were significantly associated with PA, in addition to the
nonmodifiable factors of age and sex. A limitation to this analysis was that the
majority of the included studies were cross sectional, used subjective measures
(i.e. participant-reports) of PA, or included only those in the chronic (i.e. > 6
months) phase of stroke. Ideally, identification of people with stroke at risk for
leading insufficiently active lifestyles would be done as close to stroke onset as
possible. In this manner, individualized education and behavioral interventions
could be implemented early for those most at risk for poor health outcomes
associated with physical inactivity.
The purpose of the present study was twofold: 1) determine which factors
(both nonmodifiable and modifiable) present at two months post-stroke can
predict daily step counts at one year post-stroke and 2) determine a daily step
threshold at two months post stroke that corresponds to obtaining >6000 daily
steps at one year post-stroke.
METHODS
Study Design and Participants
The present study is a secondary analysis of deidentified data from the
National Institute of Neurologic Disease and Stroke’s (NINDS) Archived Clinical
Research data (Locomotor Experience Applied Post-Stroke [LEAPS], Pamela W.
Duncan, PhD, PT, NCT00243919) received from the Archived Clinical Research
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Dataset website. The LEAPS trial was a three arm, single blinded, phase III
randomized controlled trial, which examined the effects of three interventions
(early body weight–supported treadmill training at two months post-stroke, late
body weight–supported treadmill training at six months post-stroke, and a
progressive supervised home exercise program) on self-selected walking
speed.16 Adults were screened between 5 and 30 days after experiencing an
initial stroke and, after a baseline assessment at two months post-stroke,
randomized to one of the three groups. Each intervention consisted of 36
sessions lasting 90 minutes each and performed for a total of 12 to 16 weeks.
Results demonstrated no superiority of any treatment group, with 52% of all
participants transitioning from a walking speed of [<0.40 m/s to >0.40 m/s] or
[between 0.40 m/s to <0.80 m/s] to >0.80 m/s. In addition, 52% of participants
attained clinically meaningful improvements in daily steps at one year poststroke. During the trial, 82% of participants received physical therapy (outside of
study) with 74% of therapy provided in an outpatient setting between two and six
months post-stroke.16 Ethical approval for the LEAPS trial was obtained from
several associated institutional review boards and all participants provided
informed consent prior to participation.16 The secondary analysis used in the
present study was not considered human subjects research and received
exemption from the University of South Carolina’s institutional review board.
Criteria for inclusion and exclusion in the LEAPS trial have been
reported.16,89 To be included in the trial, participants had to have a first time
diagnosis of ischemic hemorrhagic stroke, be able to walk at least 3m with or
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without help from another person and have a self-selected walking speed of
<0.80m/s. Eligible participants were then randomized to one of three treatment
groups. Participant data was collected at multiple time points during the trial but
the present study analyzed only data at baseline (two months post-stroke) and
one year post-stroke (the final assessment).
Daily Step Counts
Daily steps were measured on two consecutive days at baseline (two
months post-stroke) and at one year post-stroke using the highly reliable90,91 and
valid23,92 StepWatch Activity Monitor (Orthocare Innovations, Oklahoma City, OK,
USA). Participants were instructed to wear the monitor on the non-paretic ankle
during all waking hours with the exception of water-based activities (e.g., bathing
or swimming).93 For step data to be considered valid for the present study,
participants needed two days of monitoring94 with an overall average monitor
wear time of at least 10 hours95 at two months and at one year post-stroke. The
average daily step count for the two days of monitoring was used for analysis.
Participants without valid step data were excluded.
Candidate Predictors of Daily Steps – Nonmodifiable
Nonmodifiable factors previously found to be associated with PA in people
with stroke were examined as potential predictors of daily steps. These factors
included age and gender (males accumulating more PA than females),88 race
and/or ethnicity (Hispanics and non-Hispanic black adults obtaining less PA than
non-Hispanic whites),96 and initial stroke severity97 (measured at the initial screen
using the National Institutes of Health Stroke Scale [NIHSS]).98,99
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Candidate Predictors of Daily Steps – Modifiable
Modifiable factors previously found to be associated with PA in people
with stroke88 were also examined as potential predictors of daily steps and
included:
Self-selected100 and fast paced24 walking speed, which were measured as
the time taken to walk 10 m (at either a self-selected or a fast pace) with an
untimed 3 m section both preceding and following the timed 10 m section.89
The Six Minute Walk test101 which assessed walking endurance by having
participants walk as far as they could in 6 minutes using a standardized
protocol.26 A path of ~30 m (100 ft) was used for the test and results were
recorded as meters walked.
The Lower extremity Fugl-Meyer Assessment102 which assessed motor
impairment with scores ranging from 0 to 34, with higher scores indicating less
impairment.
The Berg Balance Scale103 which assessed balance and consists of 14items scored 0 to 4 with a maximum score of 56 (indicative of higher balance and
mobility).
Cardiorespiratory fitness which was assessed via an exercise tolerance
test (stationary bicycle) performed just prior to randomization.89,104 Participants
began pedaling at 40-60 revolutions per minute with increasing workload
increments of 10 watts per minute. The test was stopped when maximum effort
was reached (defined as reaching 90% of age predicted maximum heart rate or a
rating of perceived exertion54 of 18/20 in those taking beta blockers) or if
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symptoms limited completion of the test (e.g. a blood pressure reading that
warranted cessation of exercise). Exercise duration during the test was recorded
and used for analysis.
The Activities Specific Balance Confidence Scale,105 which is a
participant-reported measure that asks participants to rank their level of
confidence for performing 16 different tasks (e.g. walk around the house and
walk up and down a ramp). Scores range from 0 to 100% with higher scores
indicating greater balance confidence.
The Patient Health Questionnaire (PHQ-9),106 which is a 9 item participant
reported measure examining the presence and severity of depressive symptoms
with a score >10 suggestive of major depression.
The Stroke Impact Scale (mobility and participation dimensions),107 which
is a participant-reported measure examining disability and health related quality
of life with higher scores indicating less disability and greater quality of life.
Daily Steps at two-months post-stroke was also examined as a candidate
predictor of future PA and was measured via activity monitor.
Additionally, in older adults, being married,108 employed, and having a
higher level of education has also been associated with increased PA 109 and
were considered candidate predictors of daily steps.
Data Analysis
A priori power analysis using G*Power was performed to determine the
sample size needed to achieve an R2 value of 0.25 (effect size f2 of 0.33), with 18
tested predictors and power set at 0.80. An R2 value of 0.25 was chosen based
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on a meta-analysis which showed that most factors explained <30% of the
variance in PA in people with stroke.88 The minimum sample size needed to
conduct the analysis was determined to be 77 participants.
Univariate analysis using Pearson’s r (or Spearman’s rho [rs] for ordinal
data) was performed to determine the association between candidate predictors
(independent variables assessed at two months post-stroke) and average daily
step counts at one year (dependent variable). Candidate predictors found to be
statistically significantly associated (P<0.05) with daily step counts were entered
into multivariate analysis with dummy coding applied for categorical predictors.
Forward selection stepwise regression determined the strongest predictors (i.e.
largest R2 values) of daily steps at one year post-stroke, using a probability of
<0.05 for a predictor to enter the model and >0.10 for a predictor to be removed.
Forward selection was used to minimize the number of predictors in the model
and arguably make assessment of such predictors more clinically feasible (i.e.
clinicians will need to assess fewer factors to gain insight into future PA levels).
Predictors found to exhibit multicollinearity (determined as a variance inflation
factor or VIF >5)110 were removed from the model.
Step data at one year post-stroke was used to classify participants into
two groups (participants with <6000 and participants with >6000 daily steps) and
descriptive statistics were calculated. A step count of 6000 was chosen as it has
been found to be related to a decreased risk for subsequent cardiovascular
disease (i.e. stroke and myocardial infarction) in people with stroke.85
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Demographic variables between the two groups were compared through
independent t-tests or Mann-Whitney U tests, and chi-squared tests.
To determine a daily step threshold at two months post-stroke
(independent variable) which corresponds to obtaining >6000 steps at one year
post-stroke (dependent variable), receiver operating characteristic (ROC) curves,
including the area under the curve (AUC) were generated.56 Sensitivity,
specificity, likelihood ratios and Youden’s index (J)57 were calculated. J can be
used to identify optimal thresholds for diagnostic tests.58 The highest J value was
chosen as the optimal threshold to accurately classify participants as obtaining
<6000 or >6000 daily steps. All data were analyzed using IBM SPSS Statistics
for Macintosh, Version 26.0 (IBM SPSS, Chicago, IL, USA).
RESULTS
A flow diagram of how participant data were used is displayed in Figure 1.
After removal of participants with invalid data and a single outlier (in terms of
daily steps), data from 206 participants were analyzed (in Table 1). Participants
averaged 63 years of age with a median self-selected walking speed of 0.42m/s
and an average of 2922 daily steps.
Eight modifiable factors at two months post-stroke were found to be
significantly associated with daily steps at one year post-stroke: self-selected
(r=.371, p=<0.001) and fast paced (r=.401, p=<0.001) walking speed, walking
endurance (r=.476, p=<0.001), lower extremity impairment (rs=.308, p=<0.001),
balance (rs=.473, p=<0.001), average daily steps at two-months (r=.598,
p=<0.001), participant reported mobility (rs=.257, p=<0.001), and balance
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confidence (r=.231, p=<0.001). The only nonmodifiable factor significantly
associated with daily steps at one year post-stroke was initial stroke severity (rs=.333, p=<0.001). Forward selection regression was performed using these 9
factors. The first to enter in the model was average daily steps at two months
post-stroke which yielded an adjusted R2 of 0.36. The final model added balance
(Berg Balance Scale score) and increased the adjusted R2 to 0.39 (increase of
0.03); both models were significant at p=<0.001. No other factors significantly
increased R2 and no multicollinearity was observed. The final regression equation
is below and a graphical representation of the equation is shown in Figure 2.
Predicted daily steps at one year-post stroke=
1031 +0.56(daily steps at two months post-stroke)+47(Berg Balance Scale
score)
Descriptive data and a comparison of participants with <6000 and >6000
daily steps at one year post-stroke is displayed in Table 2. Participants with
<6000 daily steps at one year had slower walking speeds, less walking
endurance, greater lower extremity impairment, greater balance impairment, less
balance confidence, greater self-reported mobility limitations and an increased
initial stroke severity at two months post-stroke as compared to those with >6000
daily steps. The step count with the highest J value was 1632 steps, which had a
corresponding sensitivity of 86% and specificity of 54% (Table 3).
DISCUSSION
The present study utilized longitudinal data from the LEAPS trial to
determine which factors present early after stroke were predictive of future PA
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(i.e. daily steps). A total of 18 nonmodifiable and modifiable factors were
examined as potential predictors of daily steps at one year post-stroke, nine of
which had significant associations with daily steps. However, only daily steps and
Berg Balance Scale score at two months post-stroke remained in the final
prediction model, which accounted for 39% of the variance in daily steps at one
year post-stroke.
Previous research examining prediction, rather than association, of PA
post-stroke is limited. A recent study examined daily steps in people with stroke
after discharge from inpatient rehabilitation and again three months later.111
Predictors of daily steps at follow up included self-selected walking speed and
balance. A separate twelve month exercise intervention study found that walking
endurance, balance and health related quality of life explained 33% of the
variance in daily steps one year later.112 While an R2 value of 33% is similar to
our 39%, the previous study involved individuals with chronic stroke as opposed
to our study which followed individuals from the subacute (i.e. between two
weeks and six months post-stroke) to chronic (i.e. >six months post-stroke)
phase of stroke.113 While walking ability can be improved years after stroke
onset,114 the majority of recovery happens within the first six months.115 Thus, for
providers treating individuals with stroke in the sub-acute phase, our results may
be more pertinent. Clearly, evidence supports assessment of both walking ability
and balance early and often during stroke recovery. However, if PA is the primary
outcome of interest, our results indicate that there is no greater predictor of future
PA levels than PA levels at two months post-stroke, and therefore PA levels
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should be assessed to gain insight into future PA. Fortunately, assessment of PA
and specifically steps, is becoming easier with the use of commercially available
wearables116 that provide users with a single metric that may be used to set
goals and track progress with PA.
While participants’ balance scores explained only an additional 3% of the
variance in daily steps at one year post-stroke, balance is consistently related to
daily steps post-stroke and therefore important to assess. Numerous studies
have found that greater balance is related to greater PA, including daily
steps.111,112,117,118 In our sample, participants who did not reach at least 6000
daily steps at one year post-stroke, had poorer balance scores (median of 39/56)
than those who did reach 6000 steps (median of 46/56). Both elderly adults and
individuals with acute stroke who score <45 on the Berg Balance Scale are at a
heightened risk for falls119 and this could have negatively impacted PA levels.
Previous falls and a fear of falling are associated with reduced daily steps in
older adults.120 This finding is supported by decreased balance confidence
scores observed for participants with less than 6000 daily steps. Collectively,
balance is an important metric to measure after stroke, not only to assess fall risk
but also to gain additional insight into future PA levels.
PA is immensely beneficial in all stages of stroke recovery, with
performance of additional PA providing additional health benefits.121 Despite this,
nearly three fourths of our participants obtained <6000 daily steps at one yearpost stroke. The daily step count found in the present study is consistent with
other literature28 but also surprising considering our participants engaged in 36
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sessions of supervised, structured and progressive exercise. While the majority
(52%) of participants in the LEAPS trial had clinically meaningful improvements
in daily steps (regardless of group allocation),16 the intervention’s main purpose
was to increase walking ability (chiefly, walking speed) not daily walking
behavior. There is growing evidence that combining aerobic exercise (i.e.
walking) with a behavioral change intervention improves PA levels after stroke.32
These findings however, remain to be seen in the acute and subacute phases of
rehabilitation, where providers are focused on restoring patient function, rather
than improving overall fitness or PA levels.122 For providers working with
individuals in the subacute phase of stroke, encouraging >1632 daily steps can
serve as a preliminary target that corresponds to reaching >6000 daily steps at
one year. Future research examining the utility of >1632 daily steps will be
required to support or refute our findings, followed by interventions to determine if
achieving 1632 daily steps is feasible and effective at improving health after
stroke.
Daily step counts can provide valuable insight into future health outcomes
but much of our understanding comes from populations without cardiovascular
disease. For example, in adults at risk for type 2 diabetes, increasing daily steps
by 2000 was associated with an 8% reduction in cardiovascular events.66 To our
knowledge, only one study to date has examined the relationship between step
count and subsequent cardiovascular events in people with stroke. Kono et al85
assessed participants’ daily steps at three months and again at three years poststroke and found that 6000 daily steps was predictive of future cardiovascular
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events. Their sample, however, consisted of higher functioning individuals with
mild disability. In contrast, the present sample consisted of participants with a
variety of functional levels and only followed participants up to one yearpoststroke. As a result, long-term outcomes such as cardiovascular events could
not be assessed. Additional longitudinal studies with longer follow up periods will
be required to determine the role daily steps play in terms of subsequent stroke
risk, which is a stroke research priority.123
Strengths & Limitations
A major strength of the present study is the large sample size, which
allowed adequate power to examine numerous predictors of PA. Additional
strengths include the use of an objective activity monitor to measure steps and
assessment of individuals with moderate to severe gait impairments (i.e. gait
speed <0.8m/s). Still, the present study has several limitations. For one, potential
predictors of PA were limited to those collected in the LEAPS trial. Factors known
to be associated with PA such as motivation111 or fatigue124 were not examined,
nor were qualitative components such as outcomes expectations or social
support.125 Additional details on what precluded participants from performing
more PA may help guide interventions. In addition, our findings only apply to
participants who adhered to wearing the activity monitor at both two months and
one year post-stroke. Previous research using data from the LEAPS trial found
that adherence to wearing the activity monitor was reduced in younger
participants with reduced balance confidence and walking endurance.93 Because
of non-adherence, the original LEAPS sample size of 408 was reduced to 206 for
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the current analysis. Finally, we chose 6000 daily steps as a metric of a positive
outcome (i.e. reduced risk of subsequent cardiovascular event) but this number
was based on a single study. Thus, our resulting threshold of 1632 daily steps (at
two months post-stroke) that corresponds to obtaining > 6000 steps at one year
post-stroke should be used with caution.
CONCLUSION
In summary, the present study found that the strongest predictors of daily
steps at one year post-stroke were daily steps and Berg Balance Scale scores
assessed at two-months post-stroke. When working with individuals with stroke
in the subacute phase, promotion of daily walking, in addition to targeted balance
interventions, may lead to future increases in PA. Though there is no consensus
as to how many daily steps people with stroke should be taking, a preliminary
target for those two months post-stroke is at least 1632 steps per day. Further
research examining daily steps in people with stroke is needed to determine
effective methods of increasing walking and the role daily steps play in health
outcomes.
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Table 3.1 Participant Descriptors At Two Months Post-Strokea
Participants
Descriptor
(N=206)b
Age, years, mean (SD)

63 (12.7)

Male, n (%)

118 (57.3)

Non-Hispanic White, n (%)

101 (49)

Married, n (%)

128 (62.1)

Employed at least part time, n (%)

104 (50.5)

Completed at least some college, n (%)

117 (56.8)

Self-selected walking speed, m/s

0.42 [0, 0.78] (0.37)

Fast walking speed, m/s

0.55 [0, 1.22] (0.49)

Walking endurance (Six Minute Walk Test), m

136.5 [0, 315] (113.5)

Cardiorespiratory fitness (maximal exercise test),
24.9 [0, 60] (30.5)
test duration, minutes
Daily steps, mean (SD)

2922 (2749)

Motor function (Lower extremity Fugl-Meyer)
Balance (Berg Balance Scale)

26 [8, 34] (9.19)
41 [0, 56] (18)

Balance confidence (Activities Specific Balance
48.5 [0, 100] (34.1)
Confidence Scale), %
Participant-reported mobility (Stroke Impact
61.1 [2.78, 100] (97.22)
Scale)
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Participant-reported participation (Stroke Impact
43.75 [0, 100] (32.03)
Scale)
Patient Health Questionnaire (PHQ-9)106

3 [0, 24] (5)

Initial stroke severity (NIHSS)

6 [0, 20] (5)

Activity monitor wear time, hours, mean (SD)

20.8 (4.8)

Abbreviations: m/s, meters per second; m, meters; NIHSS, National Institutes of
Health Stroke Scale
a Data presented as median [minimum, maximum] (IQR) unless otherwise stated
b
One outlier with 29864 steps at one year (more than 5 standard deviations from
mean of 4551 steps) was excluded from analysis.
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Table 3.2 Comparison of Descriptors At Two Months Post-Stroke Between
Those With <6000 and >6000 Daily Steps At One Year Post-Stroke.a
Participants

Participants

P

With <6000

With >6000

Daily Steps

Daily Steps

(n=149)

(n=57)

Age, years, mean (SD)

64 (13)

61 (12)

0.151b

Male, n (%)

82 (55)

36 (63)

0.292c

Non-Hispanic White, n (%)

75 (50)

26 (46)

0.544c

Married, n (%)

89 (60)

39 (68)

0.250c

Employed at least part time, n (%)

71 (48)

33 (58)

0.188c

33 (58)

0.844c

0.38 [0, 0.78]

0.49 [0.10,

0.001b

(0.38)

0.77] (0.30)

0.49 [0, 1.11]

0.71 [0.14,

(0.50)

1.22] (0.40)

121 [0, 315]

178 [0, 306]

(103)

(108)

25 [0, 60] (27)

24 [0, 55] (34)

Descriptor

Completed at least some college,
84 (56)
n (%)

Self-selected walking speed, m/s
<0.001b

Fast walking speed, m/s

Walking endurance (Six Minute
Walk Test), m

Cardiorespiratory fitness (maximal
exercise test), test duration,
minutes
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<0.001d

0.235d

Daily steps at two months post-

4761 (3267)

<0.001b

8503 (2059)

<0.001b

27 [8, 34] (8)

0.036d

46 [21, 55] (12)

<0.001d

57 [6, 100]

0.020d

2218 (2151)
stroke, mean (SD)
Daily steps at one year post2870 (1704)
stroke, mean (SD)
Motor function (Lower extremity
25 [9, 34] (10)
Fugl-Meyer)
Balance (Berg Balance Scale)

39 [0, 56] (18)

Balance confidence (Activities
Specific Balance Confidence

44 [0, 99] (33)

(41))

61 [3, 100]

67 [8, 100] (26)

0.043d

44 [6, 100] (30)

0.838d

2 [0, 18] (5)

0.664d

5 [0, 19] (4)

0.017d

20.1 (5.2)

0.170b

Scale), %
Participant-reported mobility
(Stroke Impact Scale)
Participant-reported participation

(28)
44 [0, 100]

(Stroke Impact Scale)

(34)

Patient Health Questionnaire
3 [0, 24] (6)
(PHQ-9)106
Initial stroke severity (NIHSS)

7 [0, 20] (4)

Activity monitor wear time, hours,
21.1 (4.7)
mean (SD)

Abbreviations: m/s, meters per second; m, meters; NIHSS, National Institutes of
Health Stroke Scale
a Data presented as median (minimum, maximum) unless otherwise stated.
Boldface indicates significant at p <0.05.
b
Independent samples t-test, 2-sided
c Pearson Chi-Square, 2-sided
d Independent samples, Mann-Whitney U test.
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Table 3.3 Accuracy of Daily Step Count At Two-Months Post-Stroke To Classify
Who Will Reach >6000 Steps At One Year Post-Stroke.a

AUCb
Threshold

(95% CI)

Daily Steps

0.76

1632

(0.69 to 0.83)

Sensitivity

86%

Specificity

54%

+LR

-LR

(95% CI)

(95% CI)

1.86

0.26

(1.52 to

(0.13 to

2.27)

0.50)

Abbreviations: AUC, area under the receiver operating characteristics curve;
95% CI, 95% confidence interval; +LR, positive likelihood ratio; -LR, negative
likelihood ratio
a Using the daily step count threshold of 1632 steps correctly classified 86%
(sensitivity) of participants who obtained >6000 daily steps at one year poststroke and 54% (specificity) of participants who did not. Participants who
obtained >6000 steps at one year were between 1.52 and 2.27 times more likely
to average at least 1632 steps at two months post-stroke compared to those who
did not obtain 6000 steps. Boldface indicates significant at p <0.001.
b An AUC value of 1.0 indicates a perfect diagnostic test, whereas an AUC of 0.5
is equal to chance.
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Figure 3.1 Flow Diagram of Participant Data
Abbreviations: NINDS, National Institute of Neurologic Disorders and Stroke.
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6000
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Daily Step Count
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Berg Balance Scale
Scores
30

2000
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0
Average Daily Step Count
At Two Months Post-Stroke

Predicted Average Daily Step Count
At One Year Post-Stroke

Figure 3.2 Predicted Average Daily Steps At One Year Post-Stroke Based On
Steps At Two Months and Berg Balance Scale Score.
Figure depicts arbitrary daily step counts and Berg Balance Scale scores at two
months post-stroke and how these factors may predict daily steps at one year.
Figure provides a hypothetical example of the regression equation:
Predicted daily steps at one year-post stroke=
1031 +0.56(daily steps at two months post-stroke)+47(Berg Balance Scale
score)
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CHAPTER 4: EXAMINATION OF DAILY STEPS IN PEOPLE WITH
PARKINSON’S DISEASE & STROKE
Overall, there is little evidence to guide daily step recommendations for
those with PD or stroke. For pwPD or stroke, the aforementioned studies
(Chapters 2 and 3) identified daily step counts associated with health outcomes
(meeting PA guidelines for pwPD and obtaining >6000 and perhaps reducing risk
of cardiovascular events for those with stroke). Collectively, results from both
studies can be used to inform future interventions aimed at improving PA for both
groups.
Daily Steps In People With Parkinson’s Disease
For people newly diagnosed with PD, PA can reduce symptoms and
disease progression. Results from our study found that individuals taking at least
4200 daily steps were much more likely to meet PA guidelines compared to
those who took less than 4200 daily steps. Thus, a step count of 4200 steps per
day can be used as a starting point for when a newly diagnosed individual asks,
“how much should I walk?” A step count of 4200 daily steps may also be more
realistic for individuals with greater disability who may not be able to engage in
long, intense bouts of PA. While translating PA guidelines (150 minutes of
moderate-intensity aerobic activity) into steps is salient for those who accumulate
most of their PA from walking, PA guidelines are backed by a larger body of
evidence than daily step counts. Thus, at this time it would be inappropriate to
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simply replace PA guidelines with step guidelines. Our recommendation of 4200
daily steps will need to be tested, preferably in longitudinal studies, to determine
its role in long term health outcomes including disease progression,
cardiovascular events and mortality.
Recruitment of physically inactive individuals into an exercise intervention
can be difficult, as was found with our study in Chapter 2 (75% of participants
were meeting PA guidelines at baseline). Using the entire sample of participants
with de novo PD (n=110), other authors found no differences in daily steps at the
six month assessment.14 Authors went on to suggest that those allocated to an
exercise group (i.e. high or moderate-intensity treadmill exercise) may have
reduced the number of steps taken outside the intervention so that average daily
steps remained unchanged. Our study examined daily steps in the least active
individuals (i.e. those with the least steps) and found that for those in the highintensity group, there was indeed a significant increase in both steps and MVPA.
This finding would have gone undetected if not for closer inspection of the least
active participants, who arguably stand to benefit the most form increasing PA
levels. There is overwhelming evidence of a dose-response relationship in terms
of PA and health benefits. Thus, even small increases in PA, including daily
steps, are likely beneficial and should be examined.
Daily Steps In People With Stroke
Using a sample of 206 individuals who were two months post-stroke, we
found that daily steps and balance were the strongest predictors of PA at one
year post-stroke. While many previous studies found associations between
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physical function and PA, our study represents the largest longitudinal
examination of the predictors of PA. Our results suggest that targeting PA (e.g.
daily walking) and balance at two months post-stroke may lead to higher
amounts of PA at one year. While walking is the predominant intervention
employed in rehabilitation early after stroke, much of the intervention is focused
on the quality of gait, with little to no attention paid to community walking or
overall PA levels. At first glance, our findings seem obvious: in order to walk
more in the future, you should walk more now. However, our study is the first to
explicitly determine that PA early after stroke predicts future PA. This information
may be valuable to providers working with individuals early after stroke and may
prompt the initiation of behavioral change interventions, alongside standard
rehabilitation, to improve PA and subsequent health of people living with stroke.
While we determined that 1632 steps at two months post-stroke was the
optimal step count for determining who would reach >6000 daily steps at one
year, with a sensitivity of 86%, the step count should be used cautiously. At each
assessment period, steps were only monitored for two consecutive days and thus
provide a small window in which to view PA. It is possible that our determined
step count would have been different if data were collected for a longer period of
time. Future longitudinal studies, employing repeated assessments, may provide
a more accurate account of daily stepping after stroke and better inform future
PA recommendations. Overall, few participants (

~28%) in our sample

obtained >6000 daily steps at one year. This finding reinstates the need for
interventions designed to increase PA in all stages of stroke.
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Future Directions
Using two large and publicly available datasets, the two aforementioned
studies provided meaningful insight into daily step counts in two groups of people
(pwPD and people with stroke) who face an increased risk for further disability
and death due to physical inactivity. The daily step thresholds determined in the
proposed studies may be used as preliminary targets for interventions aimed at
improving PA in pwPD and stroke. Subsequently, future research can begin to
use findings from the proposed studies to better describe daily step counts and
their relationship to overall health and wellbeing. Nevertheless, there is a dire
need for interventions that successfully increase the PA levels in both pwPD and
stroke. These interventions may begin to elucidate the relationship between daily
steps and health outcomes such as cardiovascular events, hospitalizations
and/or mortality, and improve our understanding of the true value of daily steps.
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